Pharmabcine Inc.

Y-biologics Inc.

Jae Bong Yoon

Hyuk Jin Lee

Weon Sup Lee

Sang Soon Byun

Sang Ryeol Shim

Seon Young Lee

Do Yun Kim

Jin San Yoo

Seon Hwan Oh

Jong Geun Jeong

Nam Ye Kim

Sung Woo Kim

Young Ae Lee

Sung-Woo Kim

Sang Hoon Lee

In Sook Park

Joong Kyu Kim

Youngae Lee

Jinsang Yoo

Mi Ju Park

Yeun Ju Kim

Kyung Hee Nahm

Ju Ryung Nam

Jin Sang Yoo

Bo Young Jeong

Eun Jin Lee

Jin Sook Lee

Jin Hee Choi

Jinhee Choi

Young Woo Park

Bum-chan Park

Seok Ho Yoo

Jin-San Yoo

Eun Hee Lee

Gi Sun Baek

Miju Park

Do-yun Kim

Hyuk Joon Lee

Yeon Ju Kim

Ji Hye Jeong

Ju Ryoung Nam

Mi Ae Jeon

Kyoung Hee Nahm

Eun Young Jeon

Boyoung Jeong

A bispecific antibody according to an embodiment of the present disclosure specifically binds to IL-17A and TNF-α. The bispecific antibody according to the present invention or an antigen binding fragment thereof exhibits high specificity for IL-17A and TNF-α and more favorable neutralization property compared to monospecific antibody of a prior art, and, by quickly suppressing inflammation and an immune response by inhibiting simultaneously IL-17 and TNF-α, it has an advantage of improving the treatment effect with lower dose.

Bispecific antibody specifically binding to IL-17A and TNF-α

The present disclosure relates to an antibody specifically binding to epidermal growth factor receptor variant III (EGFRvIII), to nucleic acid coding the antibody, to a vector comprising the nucleic acid, to a host cell, to a preparation method of the antibody, and to a pharmaceutical composition comprising the antibody as an active ingredient for treating a cancer or a tumor.

EGFRvIII antibody and composition comprising same

The present invention relates to a novel form of a dual-target antibody targeting VEGFR-2 and DLL4, a gene encoding the same, a recombinant expression vector including the gene, host cells transformed with the recombinant expression vector, a method of producing the dual-target antibody using the host cells, a pharmaceutical composition comprising the dual-target antibody.

Dual-target antibody targeting VEGFR-2 and DLL4 and pharmaceutical composition including same

Provided are an antibody specifically bound to c-Met (c-Met-specific antibody) or fragments thereof, and more specifically, a fully human antibody having high affinity and specificity to c-Met isolated from human Fv(ScFv) phage library, a polynucleotide encoding the antibody, a recombinant vector containing the polynucleotide, a cell transformed with the recombinant vector, and a method of producing the c-Met-specific antibody by culturing the cell, wherein the c-Met-specific antibody may effectively control activity of c-Met in vivo.

Human antibody specific to c-Met and preparation method thereof

Dual-target antibody targeting VEGFR-2 and DLL4, and pharmaceutical composition including same

Growing community of inventors

Gangwon-do, South Korea

Jae Bong Yoon